儿茶酚胺类升压药减轻Toll样受体激动剂诱导的微血管内皮细胞通透性但不影响细胞因子产生
该研究在人多供体肺微血管内皮细胞单层上,用LPS、Poly(I:C)或Pam3CSK4刺激,分别加入肾上腺素、去甲肾上腺素、血管加压素或血管紧张素II,以跨内皮电阻反映通透性。肾上腺素和去甲肾上腺素改善TLR激动剂引起的跨内皮电阻下降,而血管加压素和血管紧张素II无此效应;β1/β2受体拮抗剂减弱该保护作用,α受体拮抗剂不影响。肾上腺素和去甲肾上腺素还诱导肌动蛋白骨架重排并恢复VE-cadherin和ZO-1膜表达,但不影响细胞存活及IL-8、IL-6、CCL-2产生。提示儿茶酚胺对内皮屏障的保护与抗炎作用可能分离。
要点
- 在LPS、Poly(I:C)或Pam3CSK4刺激的人肺微血管内皮细胞中,肾上腺素和去甲肾上腺素改善跨内皮电阻下降,提示降低通透性。
- 血管加压素和血管紧张素II在相同体外模型中不影响TLR激动剂诱导的跨内皮电阻下降。
- β1和β2肾上腺素受体拮抗剂减弱肾上腺素/去甲肾上腺素的跨内皮电阻保护效应,α肾上腺素受体拮抗剂无此作用。
- 肾上腺素和去甲肾上腺素诱导肌动蛋白骨架重排并恢复VE-cadherin和ZO-1的膜表达。
- 肾上腺素和去甲肾上腺素不改变TLR激动剂诱导的IL-8、IL-6、CCL-2产生及肺微血管内皮细胞存活。
适用人群与场景
- 离体人多供体肺微血管内皮细胞单层;非临床患者人群。
诊断标准与关键阈值
- 以跨内皮电阻反映内皮通透性,跨内皮电阻下降视为通透性增加;使用电阻抗传感技术测量。
- TLR激动剂包括LPS(TLR4)、Poly(I:C)(TLR3)和Pam3CSK4(TLR2)。
处置流程与药物剂量
- 体外处理:融合的人肺微血管内皮细胞单层与TLR激动剂(LPS、Poly(I:C)或Pam3CSK4)共处理,同时加入或不加入肾上腺素、去甲肾上腺素、血管加压素或血管紧张素II。
- 原文未提及上述药物的临床剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及临床红旗征或需紧急处理的情况。
研究设计与关键结果
- 研究类型为体外细胞实验;使用人多供体肺微血管内皮细胞,非临床样本。
- 肾上腺素和去甲肾上腺素改善LPS、Poly(I:C)或Pam3CSK4诱导的跨内皮电阻下降(反映通透性降低),而血管加压素和血管紧张素II无此效应。
- β1和β2肾上腺素受体拮抗剂减弱儿茶酚胺对跨内皮电阻的效应,α肾上腺素受体拮抗剂无影响。
- 肾上腺素和去甲肾上腺素诱导肌动蛋白骨架重排并恢复VE-cadherin和ZO-1膜表达。
- 肾上腺素和去甲肾上腺素不影响TLR激动剂诱导的IL-8、IL-6、CCL-2产生及细胞存活。
证据类型、等级与局限
- 证据类型为体外细胞实验;原文未给出证据等级或推荐强度。
- 局限:体外研究,使用细胞单层而非在体模型;原文未提及样本量、中心数或临床终点。
对床旁实践的改变
- 该体外结果提示儿茶酚胺可能通过β1/β2受体稳定内皮屏障,但尚未在临床中验证,不能直接改变急诊/ICU升压药选择。
- 血管加压素和血管紧张素II在体外不改善TLR激动剂诱导的内皮通透性,但原文未提供临床适用或排除人群,不能据此推断临床疗效差异。
- 肾上腺素/去甲肾上腺素不影响TLR激动剂诱导的炎症因子产生,提示内皮屏障保护与抗炎作用可能分离,临床需结合在体证据判断。
指南或共识出处
- 原文未提及指南或共识出处;来源为Crit Care Med发表的体外研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Catecholaminergic vasopressors are the cornerstone of circulatory shock management. Nevertheless, catecholamines have problematic side effects, arousing a growing interest in noncatecholaminergic agents such as vasopressin or angiotensin-II. However, their respective effects on sepsis-associated microvascular endothelial dysfunction such as permeability or inflammation remain elusive. We investigated the role of catecholamines and other vasopressors on Toll-like receptor agonists-induced microvascular endothelial permeability and inflammation.
SETTING: University research laboratory/cell research.
SUBJECTS: Human pulmonary microvascular endothelial cells from multiple donors.
INTERVENTION: Confluent monolayers of human pulmonary microvascular endothelial cells were treated with Toll-like receptor agonists (lipopolysaccharide, Poly[I:C], or tripalmitoyl-S-glyceryl cysteine) in the presence or absence of epinephrine, norepinephrine, vasopressin, and angiotensin-II. Permeability was inferred from transendothelial resistance, measured using electrical cell impedance sensing, where decreased transendothelial resistance is consistent with increased permeability. Cell-cell junction molecule expression was assessed via immunofluorescence microscopy and flow cytometry. We quantified cytokines in supernatants of Toll-like receptor agonist-treated human pulmonary microvascular endothelial cells.
MEASUREMENTS AND MAIN RESULTS: Epinephrine and norepinephrine both ameliorate lipopolysaccharide, polyinosinic:polycytidylic acid, or tripalmitoyl-S-glyceryl cysteine-induced reductions in transendothelial resistance, a surrogate for endothelial permeability. In contrast, the noncatecholaminergic agents, vasopressin, and angiotensin-II did not affect Toll-like receptor agonists-induced reductions in transendothelial resistance. β1- and β2-adrenergic receptor antagonists reduced the effects of the catecholamines on transendothelial resistance, whereas α-adrenergic receptor antagonists did not. We observed that epinephrine and norepinephrine induced actin cytoskeletal rearrangement and normalized the membrane expression of proteins involved with adherens-junctions (vascular endothelial-cadherin) and tight-junctions (zona occludens-1). Despite having a substantial effect on endothelial permeability, epinephrine and norepinephrine did not affect human pulmonary microvascular endothelial cell survival or production of interleukin-8, interleukin-6, or monocyte chemoattractant protein-1 (CCL-2) induced by Toll-like receptor agonists, suggesting that these functions are regulated separately from permeability.
CONCLUSIONS: Our findings demonstrate that treatment with epinephrine or norepinephrine strongly reduces endothelial permeability induced by agonists of multiple Toll-like receptors (Toll-like receptor-2, Toll-like receptor-3, Toll-like receptor-4) in vitro. Our studies suggest that both β1- and β2-adrenergic receptors mediate the stabilizing effects of epinephrine and norepinephrine on the endothelial barrier.
参考来源
- Joffre J, Lloyd E, Wong E, et al. Catecholaminergic Vasopressors Reduce Toll-Like Receptor Agonist-Induced Microvascular Endothelial Cell Permeability But Not Cytokine Production. Crit Care Med. 2021. PMID: 33481407. doi:10.1097/CCM.0000000000004854
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。